Gilead Sciences And WuXi PharmaTech Enter Strategic Partnership

(RTTNews) - Gilead Sciences Inc., and WuXi PharmaTech (Cayman) Inc. (WX) announced that they have entered into strategic partnership to conduct analytical and stability studies of small-molecule new chemical entities to support global marketing applications and commercial products.

Under agreement, WuXi will equip and operate a dedicated, fully cGMP-compliant 12,500-square-foot analytical testing facility in Shanghai.

The facility will provide analytical and stability services, including analytical method development, transfer and validation for IND/NDA submissions; commercial API and drug product testing; stability studies of APIs, drug products for registration, and commercial products; and reference standard qualification.

"This strategic partnership further strengthens our close, broad-based collaboration with Gilead over many years," said Ge Li, PhD, Chairman and CEO of WuXi PharmaTech.